INOVIO PHARMACEUTICALS, INC.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA, 19462
Mailing Address 660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA, 19462
Phone 8584103134
Fiscal Year End 1231
EIN 330969592
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | January 30, 2026 | View on SEC |
| 8-K Current report of material events | January 27, 2026 | View on SEC |
| 424B5 Prospectus supplement | January 27, 2026 | View on SEC |
| 8-K Current report of material events | December 29, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | December 8, 2025 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | December 5, 2025 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | November 14, 2025 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | November 14, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 14, 2025 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | November 13, 2025 | View on SEC |
Material Events
8-K Other December 29, 2025
High Impact
- The U.S. FDA has accepted INOVIO's Biologic License Application (BLA) for INO-3107, a drug to treat recurrent respiratory papillomatosis (RRP) in adults.
- The FDA expressed preliminary concern that INOVIO has not provided enough information to justify the requested accelerated approval pathway.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.